First-in-class
-
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Congratulations to Day One Biopharmaceuticals and MabCare Therapeutics!
-
FAST FOLLOW多快算FAST？
作者：优选资本 郭宇鹏 如果说前几年与国内的新药企业交流的时候，创始人讲的更多的是如何去做一个成功的me-too产品，几乎每一个企业都会宣称他们的项目将成为这一…
